AIM ImmunoTech Inc.
For the period ended Dec 31, 2025. Filed Mar 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 27, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AIM IMMUNOTECH INC. | |
|---|---|
| By: | /s/ Thomas K. Equels |
| Thomas K. Equels | |
| Chief Executive Officer | |
March 27, 2026
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange of 1934, as amended, this report has been signed below by the following persons on behalf of this Registrant and in the capacities and on the dates indicated.
| /s/ Thomas K Equels | Chief Executive Officer & President, | March 27, 2026 |
|---|---|---|
| Thomas K. Equels | Director of the Board | |
| /s/ William Mitchell | Chairman of the Board | March 27, 2026 |
| William Mitchell | and Director | |
| /s/ Robert Dickey IV E | Chief Financial Officer | March 27, 2026 |
| Robert Dickey IV | ||
| /s/ Nancy Bryan E | Director | March 27, 2026 |
| Nancy Bryan | ||
| /s/ Ted D. Kellner E | Director | March 27, 2026 |
| Ted D. Kellner | ||
| /s/ David Chemerow | Director | March 27, 2026 |
| David Chemerow | ||
AIM IMMUNOTECH INC. AND SUBSIDIARIES
Index to Consolidated Financial Statements
| Page | |
| Report of Independent Registered Public Accounting Firm (BDO USA, P.C.; Miami, Florida; PCAOB ID #243) | F-2 |
|---|---|
| Consolidated Balance Sheets at December 31, 2025, and 2024 | F-4 |
| Consolidated Statements of Operations for each of the years in the two-year period ended December 31, 2025 | F-5 |
| Consolidated Statements of Changes in Stockholders’ Deficit for each of the years in the two-year period ended December 31, 2025 | F-6 |
| Consolidated Statements of Cash Flows for each of the years in the two-year period ended December 31, 2025 | F-7 |
| Notes to Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.